Evidence map›Paper›PMID 40216650›Full record

ArticleAnnals of intensive care2025

Impact of aminoglycosides on survival rate and renal outcomes in patients with urosepsis: a multicenter retrospective study.

David Rozenblat, Arnaud Serret-Larmande, Alexis Maillard, Romain Arrestier, Sarah Benghanem, Julien Charpentier, Michael Darmon, Vincent Das, François Dépret, Jean Luc Donay and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. CHBiosensors · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

David RozenblatService de Maladies infectieuses et Tropicales, Hôpitaux Universitaires Saint-Louis Lariboisière, Assistance Publique - Hôpitaux de Paris, 75010, Paris, France. david.rozenblat@aphp.fr.ORCID http://orcid.org/0009-0006-7771-0053
Arnaud Serret-LarmandeService de Biostatistiques et Information Médicale, Hôpitaux Universitaires Saint-Louis Lariboisière, Assistance Publique - Hôpitaux de Paris, 75010, Paris, France.
Alexis MaillardService de Médecine Intensive Réanimation, Hôpitaux Universitaires Saint-Louis Lariboisière, Assistance Publique - Hôpitaux de Paris, 75010, Paris, France.
Romain ArrestierService de Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris, 94010, Créteil, France.
Sarah BenghanemService de Médecine Intensive Réanimation, Hôpitaux Universitaire Paris Centre, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, 75014, Paris, France.
Julien CharpentierService de Médecine Intensive Réanimation, Hôpitaux Universitaire Paris Centre, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, 75014, Paris, France.
Michael DarmonService de Médecine Intensive Réanimation, Hôpitaux Universitaires Saint-Louis Lariboisière, Assistance Publique - Hôpitaux de Paris, 75010, Paris, France.
Vincent DasService de Médecine Intensive Réanimation, Centre Hospitalier Intercommunal André Grégoire, Groupe Hospitalier de Territoire Grand Paris Nord-Est, 93100, Montreuil, France.
François DépretService d'Anesthésie-Réanimation et traitement chirurgical des grands brûlés, Hôpitaux Universitaires Saint-Louis Lariboisière, Assistance Publique - Hôpitaux de Paris, 75010, Paris, France.
Jean Luc DonayService de Bactériologie, Hôpitaux Universitaires Saint-Louis Lariboisière, Assistance Publique - Hôpitaux de Paris, 75010, Paris, France.
Hervé JacquierService de Bactériologie, Hôpitaux Universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris, 94010, Créteil, France.
Hélène PoupetService de Bactériologie, Hôpitaux Universitaire Paris Centre, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, 75014, Paris, France.
Jean-Michel MolinaService de Maladies infectieuses et Tropicales, Hôpitaux Universitaires Saint-Louis Lariboisière, Assistance Publique - Hôpitaux de Paris, 75010, Paris, France.
Matthieu LafaurieService de Maladies infectieuses et Tropicales, Hôpitaux Universitaires Saint-Louis Lariboisière, Assistance Publique - Hôpitaux de Paris, 75010, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCombination therapy with a beta-lactam and an aminoglycoside is currently recommended for the empirical treatment of urosepsis. Nephrotoxicity is the most common adverse effect of aminoglycosides and acute kidney injury (AKI) has a significant prognostic impact in septic shock. This study aimed to evaluate the impact of empirical antibiotic therapy with or without an aminoglycoside on survival and renal outcomes in patients admitted to the intensive care unit (ICU) with urosepsis.

methodsThis multicenter, retrospective, comparative study included all adults admitted to the ICU for urinary sepsis or septic shock between January 2015 and May 2022 in four ICUs of three university hospitals within the Assistance Publique-Hôpitaux de Paris (APHP). The primary outcome was mortality on day 30 after ICU admission. Secondary endpoints included the lack of renal recovery, the need for new renal replacement therapy (RRT), the Major Adverse Kidney Events at day 30 (MAKE 30) and ICU length of stay. Confounding by indication was taken into account using propensity score weighting.

resultsA total of 580 patients were included, median age was 69 years (interquartile: 58-77) and 53.6% were male. Overall, 335 patients (57.8%) were in septic shock and 448 (79.2%) had AKI on admission. A total of 579 patients (99.8%) received a beta-lactam as empirical therapy (with (n = 444) or without (n = 136) aminoglycosides). The overall 30-day mortality rate was 10.5% (61/580). After propensity score weighting, the mortality rate in patients receiving aminoglycosides was 7.7% (7/91) compared to 12.1% (11/91) in those not receiving aminoglycosides (adjusted hazard ratio (aHR) = 0.65 [0.35; 1.23], p = 0.19). No significant differences were found in the lack of renal recovery at day 30 (aHR = 0.88 [0.49; 1.58], p = 0.67), the need for new RRT within 30 days (aHR = 1.01 [0.54; 1.88], p = 0.97), MAKE 30 (aHR = 0.94 [0.60; 1.50], p = 0.81), and ICU length of stay among survivors (aHR = 1.07 [0.87; 1.31], p = 0.53).

conclusionsIncluding aminoglycosides in the empirical antibiotic therapy did not significantly improve 30-day survival in patients admitted to the ICU for urosepsis. However, the use of aminoglycosides was not associated with worse renal outcomes.

Indexed as

Acute kidney injuryAminoglycosidesMortalitySeptic shockUrinary tract infections

Identifiers

PMID40216650
PMCPMC11992283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.